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A best evidence topic was written according to a structured protocol. The question addressed was
whether endoscopic mucosal resection (EMR) for early oesophageal cancer gives equivalent oncological
outcomes as compared to oesophagectomy. A total of 340 papers were found using the reported searches
of which 7 represented the best evidence to answer the clinical question. The authors, date, journal,
study type, population, main outcome measures and results are tabulated. Oesophagectomy with lymph
node dissection for early oesophageal cancer is the standard to which every other treatment modality is
compared to. However, the associated mortality and morbidity rates highlight the need for the devel-
opment of effective, less invasive procedures. The evidence from the present review supports the use of
EMR in this context as a ﬁrst line treatment in T1a (mucosal) oesophageal cancer. The trade-off is a higher
recurrence rate which can be dealt with successfully using a tight follow-up schedule and retreatment.
The higher rates of lymph node involvement in T1b (submucosal) cancers preclude the use of endoscopic
treatment in this setting except for patients unﬁt for surgery.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
A best evidence topic was constructed according to a structured
protocol. This protocol is fully described in the International Journal
of Surgery.12. Clinical scenario
A colleague with Barrett’s oesophagus under surveillance meets
you during lunch and states that recent biopsies revealed intra-
mucosal cancer and a subsequent EUS did not demonstrate
submucosal invasion. He then asks for your opinion on whether an
endoscopic treatment with EMR would be sufﬁcient or surgicalry and Surgical Technology,
W2 1NY, United Kingdom.
, e.zacharakis@imperial.ac.uk
ciates Ltd. Published by Elsevier Lttreatment would be more appropriate. You resolve to assess the
literature yourself.
3. Three-part question
In [patients with early oesophageal cancer] do [EMR] and
[oesophagectomy] give equivalent [oncological outcomes]?
4. Search strategy
Search strategy using Medline from 1948 to December 2011
using the PubMed interface: ‘Endoscopic therapy’ AND ‘Oesopha-
gectomy’ AND ‘Early oesophageal cancer’. Reference lists of key
articles were also searched for references.
5. Search outcome
A total of 340 papers were found using the above search. After
reviewing the abstracts 24 papers were selected to be fully
appraised in view of relevance and methods used. Based on design,d. All rights reserved.
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and national registries) 7 papers written in English were identiﬁed
that provided the best evidence to answer the question. These are
presented in Table 1.
6. Discussion
There is no randomised controlled trial to this date addressing
the issue of endoscopic mucosal resection (EMR) vs oesophagec-
tomy for early oesophageal cancer. Moreover, the observed
heterogeneity among the relevant studies makes their interpreta-
tion difﬁcult.
Identiﬁcation of low-risk oesophageal cancers gives these
patients the best chance of being treated successfully by complete
local excision, thus leading to optimal preservation of organ func-
tion and avoiding potential peri-operative complications. The
presence of lymphatics in the deep mucosa renders oesophagus
unique among viscous hollow organs of the gastrointestinal tract.
In this context, studies like the one by Cen et al.2 that retrospec-
tively studied the lymph node metastasis (LNM) and lymphovas-
cular invasion status (LVI) in the largest group of T1 oesophageal
cancers, aid signiﬁcantly in decision making. In this study, it was
demonstrated that LNM rate is 4% in the T1a group (invasion up to
muscularis mucosa) as compared to 26% in T1b patients (invasion of
the submucosa) with subsequent implications on recurrence rate
and overall survival. These ﬁndings are in accordance with the
existing literature on the subject.3,4,5 It has also been proved that
previous EMR does not preclude subsequent oesophagectomy.6
Hence, if pathology demonstrates a higher stage than initially
perceived a completion oesophagectomy can follow. As a result,
contemporary clinical practice endorses oesophagectomy with
radical lymph node clearance for T1b tumours, whilst both oeso-
phagectomy and EMR may be contemplated for T1a tumours. This
is also incorporated in oesophageal cancer treatment guidelines
such as the NCCN guidelines.7
Pech et al.8 retrospectively reviewed 114 patients with T1a
oesophageal adenocarcinoma on the background of Barret’s
oesophagus that underwent either oesophagectomy (n ¼ 38) or
EMR plus argon-plasma-coagulation (APC, n ¼ 76), in two high
volume centres in Germany between 1996 and 2009. Median
follow up was 3.7 and 4.1 years respectively, with a strict follow-up
program implemented after endoscopic treatment. Both modalities
proved equally effective and no tumour related mortality was
observed in either group. Long-term complete remission [CR] was
100% for surgical and 98.7% for endoscopic treatment (one patient
died of other causes before CR was achieved). Five year overall
survival was 89% for EMR and 93% for surgery (p ¼ 0.91). Surgery
was associated with higher morbidity (major complications 32%)
and procedure related mortality risk (2.6% at 90 days). On the other
hand, EMR plus APC was safer (0% major complications) with the
disadvantage of higher relapse rate (6.6%), requiring repeat endo-
scopic treatment which was feasible and successful in all cases. No
patient required oesophagectomy after initial EMR.
Prasad et al.9 compared the long-term outcomes of 178 patients
treated either endoscopically (n ¼ 132, EMR or EMR plus photo-
dynamic therapy [PDT]) or surgically (n ¼ 46, transthoracic or
transhiatal route) for T1a oesophageal adenocarcinoma with
amean follow up period of 43 and 64months respectively. Five year
overall survival was 83% in the EMR and 95% in the surgery group
(p < 0.001) and cumulative mortality was 17% and 20% respectively
(p ¼ 0.75). A higher recurrence rate was detected in the EMR group
(12%) requiring repeat endoscopic treatment. Complication rate
was higher with oesophagectomy (34% vs 13% for EMR). The study
is limited by the smaller number of patients and longer Barrett’s
oesophagus segment in the oesophagectomy arm. On the otherhand, patients treated endoscopically were older (mean age of 71.2
vs 67.7, p ¼ 0.006) with more comorbidities.
Das et al.10 retrospectively reviewed 742 patients registered
between 1998 and 2003 with the diagnosis of Tis (high grade
dysplasia, 17.7%) or T1N0M0 (mucosal-submucosal, 82.3%) oeso-
phageal cancer in the Surveillance Epidemiology and End Results
database (SEER) of the National Cancer Institute in the USA. The
histologic type was non-squamous in 83.7% of patients (mainly
adenocarcinoma) and squamous in 16.3%. The patients received
either surgical (86.7%) or endoscopic therapy (13.3%). In the latter
group 65.7% underwent EMR, 14.1% EMR plus ablation [thermal or
photodynamic therapy (PDT)] and 16.2% solely ablation. Endoscopic
therapy was not speciﬁed in 4 patients. The conclusion was that
EMR and surgery are equally effective. Median oesophageal cancer-
free survival was 59 months in the surgical resection group versus
56 months in the endoscopic therapy group (primary outcome,
p ¼ 0.41). Oesophageal cancer-speciﬁc mortality was similar for
endoscopic and surgical treatment with a relative hazard [RH] of
0.89 (95% conﬁdence interval [CI] 0.51e1.56, P ¼ 0.68). Limitations
include the lower percentage of patients and inhomogeneous
treatment in the endoscopic therapy group, and the lack of data on
provider- and hospital-level. With regard to the primary outcome
all histologic types were grouped together and no separate analysis
was performed. The same applies to T1a/T1b cancers. The exclusion
of 20 patients that were not treated with EMR did not affect the
overall conclusion.
Schembre et al.11 conducted a retrospective review of a single
institution’s experience in endoscopic and surgical treatment with
curative intent of patients with Barrett’s oesophagus and high
grade dysplasia (HGD, n ¼ 63) or intramucosal adenocarcinoma
(IMC, n ¼ 30). A total of 62 procedures were completed endo-
scopically (18 EMR, 22 EMR plus PDT, 20 PDT and 2 APC) and 32
surgically (4 transhiatal, 10 Ivor-Lewis, 18 left thoracoabdominal).
The median follow-up was 20 months for endoscopic treatment
and 48 months for oesophagectomy. Overall 4-year adjusted
survival rate was 89% for endotherapy and 93% for surgery
(p ¼ 0.49) with no deaths attributed to oesophageal cancer for
either group. Eight patients with HGD in the endotherapy group
underwent further endoscopic therapy for residual disease. Cancer
developed in 6% of patients with an initial diagnosis of HGD that
were treated endoscopically (1 IMC that underwent repeat endo-
therapy, 1 IMC that opted for surgery and 2 invasive cancers that
received chemoradiation). One patient in the surgical group with
persistent HGD proximal to a high anastomosis was treated
successfully endoscopically. For endoscopic treatment, procedure
relatedmortality was 2% (1 patient died of sepsis from diverticulitis
11 days after treatment), major complications were 8% and minor
complications 32%. The respective percentages for oesophagectomy
were 0%, 13% and 66%. Authors conclude that endoscopic therapy is
equally effective. The study is limited by the inhomogeneous
treatment modalities, higher patient age (70 vs 64 years) and
relatively short follow-up in the endotherapy arm. Also, by the
small numbers and the retrospective design.
Paciﬁco et al.12 retrospectively analysed the results of either EMR
plus photodynamic therapy (PDT) or oesophagectomy in 88 patients
with early adenocarcinoma (T1a/T1b) on a background of Barrett’s
oesophagus. Twenty-four received endoscopic therapy while the
rest underwent surgery. Mean follow-up timewas 19months in the
oesophagectomy and 12months in the EMR/PDTgroup. Treatment-
related complication rate was higher in the oesophagectomy group
(31%vs4%) and1procedure relateddeathwas observed (vs0). In the
EMR/PDTgroup persistent adenocarcinomawas found in 4 patients
(17%) on the ﬁrst follow-up examination (1 underwent oesopha-
gectomy, 1 received chemoradiation as a high-risk surgical candi-
date and two died of causes unrelated to cancer progression or to
Table 1
Best evidence papers.
Author, date and
country, study
type (level of
evidence)
Patient group Outcomes Key results Comment
Pech et al. 20118
Ann Surg.
Germany
Retrospective
cohort study
(Level 3
evidence)
A total of 114 patients with mucosal BC who
were treated either surgically or
endoscopically between 1996 and 2009 in
two high-volume centers.
Thirty-eight patients received transthoracic
esophageal resection with 2-ﬁeld
lymphadenectomy (median 29 lymph nodes
removed; all pN0).
Seventy-six patients treated with EMR
followed by argon-plasma-coagulation of
the remaining non-dysplastic Barrett’s
oesophagus.
Patients were matched according to age,
gender, inﬁltration depth (pT1m1-3),
differentiation grade (G1/2 vs. 3) and
follow-up period.
The median follow-up periods were
4.1 years in the ER group and 3.7 years in
the surgical group
Complete
remission
(CR)
Major
complications
Ninety day
mortality
Overall
recurrence
rate
Disease free
follow-up
(5 years)
Overall
survival
(5 years)
Tumor related
mortality
EMR vs. Oesophagectomy
98.7% (1 patient died of other
causes before achieving CR) vs 100%
0% vs. 32% (p < 0.001)
0% vs. 2.6% (p ¼ 0.333)
6.6% (1 local, 4 metachronous
with successful repeat endoscopic
treatment in all patients)
vs. 0% (p ¼ 0.17)
91% vs 100% (p ¼ 0.19)
89% vs 93% (p ¼ 0.91)
0% in both groups.
No LNM noted in both groups.
For patients with mucosal
BC, both surgery and EMR
are effective treatment
modalities. Surgery is
associated with a higher
morbidity rate and shows a
risk for procedure-related
mortality. The recurrence
rate is higher in patients
treated with EMR, hence
thorough follow-up is
mandatory.
Prasad et al.
20099
Gastroenterology
USA
Retrospective
cohort study
(Level 3
evidence)
Retrospective analysis of 178 patients
treated for mucosal (T1a) oesophageal
adenocarcinoma between 1998 and 2007.
Patients were divided into an endoscopically
treated group (n ¼ 132, 111 male, mean age
71.2 years) and a surgically treated group
(n ¼ 46, 43 male, mean age 67.7 years).
The mean follow-up period was 64 months
(standard error of the mean 4.8 months) in
the oesophagectomy group and 43 months
(standard error of the mean 2.8 months) in
the EMR group.
Median age-adjusted Charlson
Comorbidity Index, (IQR) was 4 (0e5) in the
EMR and 0 (0e4) in the surgery arm
(p < 0.001)
Complication rate
Cumulative mortality
Cancer free survival
(5 years)
Overall survival
(5 years)
Recurrence
EMR vs. Oesophagectomy
13% vs 34%
17% vs. 20% (p ¼ 0.75)
80% vs 97% (p ¼ 0.33)
83% vs 95% (p < 0.001)
16/132 (all successfully
retreated without an
impact on survival) vs 1/46
Authors conclude that outcome
is comparable between EMR
and esophagectomy.
Limitations: Retrospective
analysis. Smaller number
of patients with longer
Barrett’s oesophagus segment
in the surgery arm. Older
patients with more
comorbidities in the EMR arm.
Cen et al. 20082
Cancer
USA
Retrospective
cohort study
(Level 3
evidence)
Ninety nine patients with T1,N0 or T1,N1
adenocarcinoma of the oesophagus or the
GOJ who underwent primary
oesophagectomy at the University of Texas
M. D. Anderson Cancer Center between
November 1988 and November 2005.
Preoperative assessment comprised upper
GI endoscopy with biopsies, EUS, CT and in
32 patients (32.3%) also a PET scan.
All 99 patients underwent resection with
lymph node dissection for curative intent.
No patient received adjuvant chemotherapy
or chemoradiation after surgery
The following data were obtained: size,
depth, location of the cancer, LVI status,
degree of differentiation, presence of
Barrett’s mucosa, margin status, and the
presence or absence of LNM
The time to relapse and location of relapse
(local and distant), the date of death, and the
cause of death were ascertained. Mean
follow up 60 months.
LNM
Overall survival
(OS) and survival
prognosis
Recurrence-free
survival (5 years)
T1a vs. T1b
4% vs 23%
88% (all non-cancer related
deaths) vs 62% 5 year
OS (p ¼ 0.001)
[T1a vs T1b without LVI
is 90% vs 77%, p ¼ 0.078.
T1b without LVI vs T1b
with LVI is 77% vs 27% p ¼ 0.006]
The multivariate analysis
demonstrated that LNM (P ¼ 0.03)
and age >65 years (P ¼ 0.04)
were independent factors that
were predictive of a poor OS.
The presence of LVI was of borderline
signiﬁcant as an independent
factor that was predictive
of poor OS (P ¼ 0.05)
100% vs 74% (T1b without LVI,
p ¼ 0.006), 35% (T1b with LVI,
p < 0.0001).
Distant metastasis in 96% of
patients with recurrence
Low risk for LNM in T1a as
compared to T1b cancers.
This endorses the concept
of less invasive procedures
such as EMR being used as
ﬁrst line treatment in
T1a cancers.
(continued on next page)
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Table 1 (continued )
Author, date and
country, study
type (level of
evidence)
Patient group Outcomes Key results Comment
Das et al. 200810
Am J
Gastroenterol.
USA
Retrospective
cohort study
(Level 3
evidence)
A total of 742 patients registered between
1998 and 2003 in the Surveillance
Epidemiology and End Results database
(SEER) of the National Cancer Institute, with
the diagnosis of Tis (high grade dysplasia) or
T1N0M0 nonsquamous and squamous
cell-type esophageal cancer
Ninety nine (13.3%) patients underwent
endoscopic treatment (group A) and the
remainder was managed by surgical
resection (group B).
Endoscopic treatment comprised EMR
(65.7%), EMR plus ablative therapy (14.1%)
and ablative therapy alone (16.2%).
Data on demographic features, tumour
characteristics, types of treatment received
(endoscopic vs surgical resection), and
cancer-speciﬁc mortality were analyzed.
Cancer speciﬁc
mortality
Median cancer-free
survival
Predictors of
survival
Endoscopic therapy vs.
Oesophagectomy
Cox proportional hazards
model demonstrates a
relative hazard [RH] of
0.89 (95% conﬁdence
interval [CI] 0.51e1.56,
P ¼ 0.68)
56 vs 59 months, p ¼ 0.41.
Signiﬁcant predictors of
survival were age at
diagnosis (RH 1.06,
95% CI 1.03e1.08, P < 0.001)
and absence of exposure
to radiation therapy
(RH 0.32, 95% CI 0.21e0.48,
P < 0.001).
Equivalent long term survival
between endoscopic therapy
and surgery in early oesophageal
cancer.
Cumulative experience from
multiple institutions, not only
highly-specialised, high-volume
centres.
First population-based data
supporting the effectiveness
of endoscopic therapy for
managing these patients.
Radiation therapy detrimental
to overall survival.
Limitations: Small percentage
of endoscopically treated patients,
with inhomogeneous treatment
modalities.
Schembre et al.
200811
Gastrointest
Endosc
USA
Retrospective
cohort study
(Level 3
evidence)
A retrospective study of 94 patients with
Barrett’s oesophagus and dysplasia or
intramucosal cancer who received either
endoscopic or surgical therapy between
1998 and 2005 was performed.
Sixty-two patients with a median age of
70 years underwent endoscopic therapy
(2 APC alone, 18 EMR þ APC, 20 PDT þ APC,
and 22 EMR þ PDT þ APC). Seventy three
percent were male. Thirty two patients
underwent oesophagectomy (93% male with
a median age of 64 years).
Average ASA level was 2.6 in the
endotherapy and 2.5 in the surgery group.
Median follow-up of 20 months for
endotherapy and 48 months for surgery.
Oesophageal
cancer-related
mortality
Thirty day mortality
Cancer recurrence
rate
Major/ Minor
complications
Median cost
Endoscopic therapy vs.
Oesophagectomy
0% in both groups
1 (2%) vs 0% (p ¼ 0.49)
6% vs 0% (p < 0.05)
8% / 31% vs 13% / 63%
(p ¼ 0.5 / p < 0.001)
$40,079 vs $66,060 (p < 0.001)
Modalities equally effective.
Higher morbidity and cost for
surgery. Higher risk of recurrence
with endoscopic therapy mandating
careful follow up.
Limitations: Retrospective analysis.
Small numbers. Relatively short
follow up with higher patient age
and inhomogeneous treatment
modalities in the endoscopic
therapy group.
Paciﬁco et al.
200312
Clin
Gastroenterol
Hepatol
USA
Retrospective
cohort study
(Level 3
evidence)
Retrospective study (1996e2001) of 88
patients with early stage BC undergoing
either EMR plus an ablative procedure
(PDT, n ¼ 24, 21 men, mean age 68 years)
or oesophagectomy (n ¼ 64, 58 male, mean
age 67 years). Follow-up of 12  2 and
19  3 months respectively.
Pulmonary comorbidities were signiﬁcantly
higher in the EMR/PDT group
(42% vs 19%, p ¼ 0.03).
Patient demographics, tumor staging,
procedure-related morbidity and mortality,
persistence or recurrence of cancer, and
cancer-related deaths after therapy were
studied.
Procedure-related
complications
Procedure-related
deaths
Failure to respond
to therapy
Cancer free at the
end of follow-up
EMR/PDT vs Oesophagectomy
31 vs 4 (p < 0.01)
0 vs 1
4 (2 underwent alternative
therapies and rendered
free of disease, 2 died of
unrelated causes) vs 0
83% (20/24) vs 100%
Endoscopic therapy appears to
constitute a viable option for
the treatment of early Barrett’s
adenocarcinoma.
Limitations: Small number of
patients in the endoscopic therapy
group. Retrospective study.
Short follow-up. Higher pulmonary
comorbidities in the EMR/PDT
group. Lack of discrimination
between T1a and T1b stage.
Fujita et al.
200113
World J Surg
Japan
Retrospective
cohort study
(Level 3
evidence)
A total of 150 patients diagnosed with T1a
(n ¼ 72) or T1b (n ¼ 78) oesophageal cancer
from 1981 to 1997 were evaluated
(17 women and 133 men, mean age of
63 years).
Mortality and morbidity rates, survival rate,
and recurrence rate were retrospectively
compared for (1) 35 patients who
underwent EMR and 37 patients who
underwent oesophagectomy for a mucosal
oesophageal cancer and (2) 45 patients who
underwent extended radical
oesophagectomy and 33 patients who
underwent less radical oesophagectomy for
a submucosal oesophageal cancer.
Follow-up of 32 months in average (4e68)
for the EMR and 62 months (1e153) for the
oesophagectomy group.
LNM
Survival (5-year)
Hospital Mortality
Morbidity
Recurrence
T1a vs T1b
1% vs 38%
EMR vs Oesophagectomy (T1a)
61% vs 71% (p ¼ NS)
No difference in disease
speciﬁc survival
0% vs 14% (p ¼ 0.017)
7% vs 69% (p < 0.001)
0% vs 0%
No difference in survival and
recurrence rates in T1a oesophageal
cancers treated with either EMR
or oesophagectomy. Signiﬁcantly
lower morbidity and mortality
with EMR. Authors conclude
that EMR should be a mainstay
treatment for T1a cancers.
Substantially lower LNM rate in
the T1a group.
Limitations: retrospective analysis.
APC ¼ Argon-Plasma-coagulation; BC ¼ Barrett’s Cancer (adenocarcinoma); CI ¼ conﬁdence interval; EMR ¼ Endoscopic Mucosal Resection; GI ¼ Gastrointestinal;
GOJ ¼ Gastrooesophageal junction; OR ¼ odds-ratio; PET ¼ positron emission tomography; PDT ¼ photodynamic therapy; LNM ¼ lymph node metastasis;
LVI ¼ lymphovascular invasion.
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during follow-up. The authors conclude that endoscopic therapy is
a viable, lessmorbid alternative to surgery.Weaknesses of the study
comprise the retrospectivedesign, the relativelyshort follow-upand
the smaller number of patients in the EMR/PDT group. Moreover,
there was a higher proportion of pulmonary comorbidities (42% vs
19%, p ¼ 0.03) in this group. No discrimination was made between
T1a and T1b stage.
Fujita et al.13 retrospectively reviewed 150 patients with T1a
(n ¼ 72) or T1b (n ¼ 78) squamous cell oesophageal cancer. The
former group received either EMR or oesophagectomy (trans-
thoracic route with lymphadenectomy in 23 and transhiatal route
without lymphadenectomy in 12 patients). The latter underwent
extended radical or less radical oesophagectomy. The average
follow-up period was 32 months (range 4e68) for EMR and 62
months (range 1e153) for surgery. There was no signiﬁcant
difference in background factors between the oesophagectomy and
the EMR group. Fifteen patients were cancer-positive at the lateral
margin after EMR, but repeated EMR, endoscopic laser vapor-
ization, or adjuvant radiotherapy were successful, so no patient
died of recurrence. Adjuvant radiotherapy was administered to 4 of
these patients because the presence of oesophageal varices or
oesophageal stricture precluded repeat EMR. There was no signif-
icant difference in the overall survival curves. The overall 5-year
survival rate after EMR was 61%, and the 5- and 10-year survival
rates after oesophagectomy were 71% and 42%. Survival of patients
with mucosal oesophageal cancer was strongly inﬂuenced by the
postoperative complications and the presence of synchronous
double primary cancers (36% of cases) but not by the treatment
modality (EMR versus esophagectomy). There was no difference
between the two modalities in disease speciﬁc survival since no
patient died of recurrence in both groups. In T1a cancers, hospital
mortality and morbidity were 0% and 7% after EMR and 14% and
69% after oesophagectomy. Of note the LNM/LN recurrence rate of
1% for T1a tumours compared to 38% for T1b. The authors, in view
of the equivalent outcomes and safety proﬁle, conclude that EMR
and extended radical oesophagectomy is the mainstay of treatment
for T1a and T1b tumours respectively. The study is limited by the
retrospective design.
Three more facts should be mentioned, that provide reason for
additional contemplation. Firstly, the Eguchi et al.14 study which
suggests a higher (18%) lymph node involvement rate in m3
(muscularis mucosa) squamous-cell oesophageal cancer, rendering
these patients unsuitable for endoscopic treatment. Secondly, the
Wiesbaden group experience which has shown that patients with
sm1 (upper third of submucosa) oesophageal adenocarcinomamay
be considered for endoscopic resection alone if the cancers are low
grade and do not demonstrate lymphovascular inﬁltration.15 And
lastly, the fact that the successful results with EMR come from high
volume, highly specialized centers which commands for caution
when applying them in clinical decision making.
7. Clinical bottom line
The lack of high level evidence in the literature highlights the
need for further studies. However, given the ethical implications,
the long follow-up time and the standardization of treatment
modalities required, such a study seems unlikely to occur in the
foreseeable future. In addition, performance of minimally invasive
oesophagectomy may shift the tables in terms of morbidity and
mortality but that remains to be proved.
Based on the available evidence, endoscopic mucosal resection
alone or combined with other endoscopic techniques represents
a viable and less invasive therapeutic option for early oesophageal
cancer. It seems to offer equivalent oncological outcomes comparedto oesophagectomy for T1a cancers, with signiﬁcantly decreased
morbidity and mortality. Endoscopic treatment appears to be
associated with higher recurrence rates, but this may be success-
fully managed in the majority of the cases with close follow-up and
repeat endoscopic treatment. On the other hand, surgery is
considered the best available treatment for T1b cancers due to the
higher incidence of lymph node involvement. In patients with T1a
oesophageal cancer an extensive discussion with the patient is
advocated, as it all comes down to choosing between a safer
procedure entailing life-long thorough follow-up with possible
reinterventions, or risking signiﬁcantly higher morbidity and
mortality for a long lasting positive treatment outcome.
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